NASHUA, N.H.--(BUSINESS WIRE)-- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces that Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will participate in an industry panel discussion on March 2, 2011 at 11:00 a.m. Eastern time at the 2011 RBC Capital Markets' Healthcare Conference being held from March 2-3, 2011 in New York City at The Palace Hotel.
An audio webcast of the panel discussion will be available live and archived for 30 days at http://www.wsw.com/webcast/rbc129/rbc129.panel2 as well as on the Investor Relations section of the Company’s website at www.icadmed.com.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent® eBx™ electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
Darlene Deptula-Hicks, 603-882-5200 x7944
For Investor Relations
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
For media inquiries
Liza Heapes, 617-369-8787
KEYWORDS: United States North America New Hampshire
INDUSTRY KEYWORDS: Technology Software Health Medical Devices Oncology Radiology